|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
June 2006FeaturesCover Story Specialty Pharmacy: Will the Promise Deliver?Specialty pharmacy worked fine when all it had to do was deliver prepackaged drugs. Many newer biologics, however, require a professional expertise that will be service-oriented and demanding. Health plans want to be sure SPs are up to the task. Benefit Design Lessons and Limitations of Moving Biologics to the Pharmacy BenefitMigrating specialty drugs from medical to pharmacy can be viewed as the first major trend in biologics-influenced health benefit design. To what result? And how far should it go? Economics Outcomes-Based Access: What Will It Mean for Biologics?Outcomes-based access is the paradigm guiding health plan decision making about access to traditional prescription drugs. Now, third-party payers are applying OBA principles to more and more biologic therapies. Clinical/Diagnostics The Collaboration of Drug Discovery and DiagnosticsAdvances in molecular diagnostics will ripple through the landscape of medicine. As these developments influence drug development, many believe the FDA will be forced to hold developers to higher standards. Business Early-Stage Biotech Companies: Strategies for Survival and GrowthA to-do checklist based on three areas that are key for navigating the industry’s stormy seas. Failure to execute in any one area could sink your ship. DepartmentsOpeners/Letter to the Editor ‘Do the Right Thing’
Michael D. Dalzell Editorial Predicting Policy for Personalized MedicineDavid B. Nash, MD, MBA, thinks about policy for personalized medicine. Washington Watch FDA Keeps Open Mind About Potential of Surrogate Endpoints
John Carroll Diagnostics and Devices Technology Forces Changes In Role and Function of P&T CommitteesBiologics forcing P&T committees to behave more like tech-review bodies. DrugTrack Approvals, FDA Actions, Clinical Trials
Bob Carlson, MHA
Biotech Business Biotech and Medicaid – the Perfect Storm?
Amanda Brower Trends Part D Coverage of RA Biologics: Dramatic Out-of-Pocket Cost Variance
Katherine T. Adams |
|||||